Partha Das
Global Medical Director, Precision Johnson & Johnson
Seminars
Wednesday 4th February 2026
Panel Discussion: Clinically Validating Liquid Biopsies for Early Clinical Endpoints in Solid Tumor to Enhance Patient Selection & Monitoring
3:15 pm
- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- Considerations into choosing the right test for the right applications.
Thursday 5th February 2026
Navigating Regulatory & Policy Hurdles to Accelerate Global Adoption of Liquid Biopsies – Chaired by
